RZLT Stock Overview
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Rezolute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.08 |
| 52 Week High | US$6.19 |
| 52 Week Low | US$0.86 |
| Beta | 1.08 |
| 1 Month Change | -16.22% |
| 3 Month Change | -15.35% |
| 1 Year Change | 353.33% |
| 3 Year Change | -12.26% |
| 5 Year Change | -18.40% |
| Change since IPO | -99.38% |
Recent News & Updates
Recent updates
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
May 22
Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate
Feb 13Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price
Sep 21Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation
Jul 25We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth
Jan 31Rezolute GAAP EPS of -$0.37
Sep 15We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
May 06Rezolute shares rise on positive topline results from RZ402 eye disease trial
May 04What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?
Jan 12Shareholder Returns
| RZLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.4% | -2.5% | 0.1% |
| 1Y | 353.3% | 3.1% | 26.1% |
Return vs Industry: RZLT exceeded the US Biotechs industry which returned 3.1% over the past year.
Return vs Market: RZLT exceeded the US Market which returned 26.1% over the past year.
Price Volatility
| RZLT volatility | |
|---|---|
| RZLT Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RZLT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RZLT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 18 | Nevan Elam | www.rezolutebio.com |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.
Rezolute, Inc. Fundamentals Summary
| RZLT fundamental statistics | |
|---|---|
| Market cap | US$257.27m |
| Earnings (TTM) | -US$69.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs RZLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RZLT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.31m |
| Earnings | -US$69.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RZLT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 22:29 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rezolute, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Edward Nash | Canaccord Genuity |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |